TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05101720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Axillary Venous Access
Description: Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-Guided Axillary Venous Access
Description: Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound
Study: NCT06102395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2, IV, day 1 of Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2, IV, day 1 of Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2, IV, day 1 of Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2, IV, day 1 of Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel
Description: Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal paclitaxel
Description: Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
Study: NCT06120296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acumen Hypotension prediction Index software
Description: In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
Study: NCT05154396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
Study: NCT04186585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C2
Description: Oral daily intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C2
Description: Oral daily intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C2
Description: Oral daily intake
Study: NCT05242289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb
Description: Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
Study: NCT06235502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based cycle-exercise for COPD patients
Description: Patients will cycle in their own home using a pedal exerciser connected to the 4M-video app

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Exercise at Fitness Center, home based exercise according to a programme
Study: NCT05130593

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutrasorb bar
Description: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
Study: NCT05375422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SARAH
Description: Set of exercises with components of muscle strengthening, range of motion gain and home exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Information related to joint protection, use of splints, assistive devices and other general advice, as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
Study: NCT05188989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 2.5mg group
Description: TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 5mg group
Description: TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 10mg group
Description: TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
Study: NCT06255795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide, anti-PD1 antibody, and pegaspargase
Description: 6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDGP
Description: 6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
Study: NCT05154396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neratinib
Description: Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
Study: NCT05537155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal acupuncture in addition to routine care
Description: Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
Study: NCT06360744

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Johnson & Johnson
Description: Vaccination with the Johnson \& Johnson vaccine which is NOT part of the Danish National Government programme
Study: NCT06390917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVA recognition function
Description: Ventilator with the function of identify and judge PVAs
Study: NCT04863924

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid Biopsy
Description: All patients will have a liquid biopsy with ctDNA molecular profiling
Study: NCT05432674

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Digital Fall Prevention
Description: Exercises delivered through a tablet and remote motivational calls
Study: NCT05786014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Walking
Description: Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
Study: NCT06257797

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test
Description: Fenugreek wiil be tested by mixing fenugreek seed powder with saline at non-irritating doses and it will be performed by prick-by-prick test. The skin tests will be read 20 minutes after the execution.
Study: NCT04897945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making for diabetes prevention
Description: Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
Study: NCT00651222

Intervention type: OTHER
Intervention: No intervention was required
Description: Death records were reviewed, therefore, there was no intervention
Study: NCT05733689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ctDNA Blood Test
Description: Blood will be collected for ctDNA testing

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FLOT
Description: * Oxaliplatin 85 mg/m2 IV on Day 1~* Docetaxel 50 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: * Oxaliplatin 85 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: * Irinotecan 180 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: * Oxaliplatin 85 mg/m2 IV on Day 1~* Irinotecan 150 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PACLITAXEL with or without CARBOPLATIN
Description: * Paclitaxel 200 mg/m2 IV on Day 1~* Carboplatin AUC 5 IV on day 1 Every 21 Days~OR~- Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days
Study: NCT04713930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT04536701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Monitoring and Behavioral Recommendation System
Description: The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
Study: NCT05733689

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DOCETAXEL and IRINOTECAN (alone or combined)
Description: * Docetaxel 35 mg/m2 IV on Days 1 and 8~* Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days~* Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days~* Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIVOLUMAB (alone or when added to a regimen above)
Description: * 240 mg IV on Day 1 every 14 days, or~* 360 mg IV on Day 1 every 21 days, or~* 480 mg IV on Day 1 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEMBROLIZUMAB (alone or when added to a regimen above)
Description: * 200 mg IV on Day 1 every 21 days, or~* 400 mg IV on Day 1 every 42 days
Study: NCT05338138

Intervention type: DEVICE
Intervention: ultrasound guided central venous catheter insertion
Description: Prospective comparative randomized controlled clinical study.
Study: NCT06160869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: The psychoeducational intervention will consist of seven structured sessions aimed at introducing patients with primary psychosis to the principles and practices of Acceptance and Commitment Therapy (ACT). The primary focus of the intervention is to empower participants to effectively manage distressing thoughts and feelings while pursuing meaningful and valued life goals. Each session covers specific aspects of ACT.~Acceptance and commitment therapy will be adminitered in addition to treament as usual provided to patients.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The treatment as usual (TAU) for all patients regardless of condition will consist of hospital treatment, including daily medication management sessions with a psychiatrist (e.g., antipsychotic and other medications as appropriate), community meetings, other group therapy, case management, occupational therapy, open air walks, discharge planning, physical examination, and other services (e.g., medical testing).
Study: NCT05945901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
Description: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
Description: HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
Study: NCT06400784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
Study: NCT05466305

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gold plated chrome cobalt alloy
Description: Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gold plated chrome cobalt alloy
Description: Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
Study: NCT06460142

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry of Temporal Artery Biopsies
Description: Immunohistochemistry staining of TAB to assess local expression of endothelial adhesion molecules in acute inflammation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional assessment questionnaires
Description: The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional assessment questionnaires
Description: The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.
Study: NCT05751486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab injection(subcutaneous)/JS001sc
Description: JS001sc Q3W combination with gemcitabine and cisplatin.
Study: NCT06441279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular injection with Platelet lysate (PL).
Description: 2 ml of Platelet lysate will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular injection with Hyaluronic Acid.
Description: 2 ml of Hyaluronic Acid will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly.
Study: NCT05751486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab injection(subcutaneous)/JS001sc
Description: JS001sc long period combination with gemcitabine and cisplatin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab /JS001
Description: JS001 IV (if applicable) .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab injection(subcutaneous)/JS001sc
Description: Additional cohort (if applicable)
Study: NCT06639633

Intervention type: OTHER
Group type: OTHER
Intervention: Anatomy Training with Enlarged %100 3D Printed Carpal Model Group
Description: After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 100% magnification on a 3D printer for 60 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Anatomy Training with Enlarged %50 3D Printed Carpal Model Group
Description: After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 30 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 50% magnification on a 3D printer for 60 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anatomy Training with Conventional Carpal Models
Description: After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. They will then have a 60 minutes practical lesson with a standard sized printed model.
Study: NCT06639464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: This intervention will consist of the FDA-approved dosing schedule, with terminal dosage based on manufacturer's recommendation to titrate to 1mg over 12 weeks. Participants will receive 0.25mg for the first 4 weeks, 0.5mg for the next 4 weeks, and 1.0mg for the final 4 weeks. IDS will extract semaglutide an draw the doses into syringes for matching placebo doses to also be produced and maintain blind.